Document is current
Any future updates will be listed below
-
Authors
Gujarathi, Rushabh
Rodman, Christopher
Bansal, Varun Vivek
Belmont, Erika
Setia, Namrata
Alpert, Lindsay
Hart, John
Möller, Mecker G.
Eng, Oliver S.
Lee, Grace
Polite, Blase N.
Turaga, Kiran K.
Shergill, Ardaman
- License Information
-
More Information
Article History
First Online: 20 January 2026
Disclosure
: Ardaman Shergill has acted in advisory and/or consultancy roles for Natera, Merus, Takeda, Ipson, Guardant, Pfizer, Amgen, Revolution Medicine, and Iterion Theraputics; has received research support to their institution from Hutchison MediPharma/Takeda, Merck, Verastem Oncology, Turning Point Therapeutics, Gritstone, Bolt Therapeutics, BMS, Pfizer, Astellas, Oncologie, Macogenics, Seattle Genetics, Amgen, Daiichi, Eli Lilly, Jacobio, AstraZeneca, Genentech, Jazz Pharma, Agenus, and AbbVie; and has received support for travel and/or speaking from the cure CRC Summit, Great Debates, OncLive, OSCO, ASCO, ACPMP, Cholangiocarcinoma Summit, Cholangiocarcinoma Foundation, ASCO Advantage, and Takeda (for AACR poster).
